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Abstract
This study investigates the association of CRP single nucleotide polymorphisms (SNPs) with 
plasma CRP levels and radiographic severity in African Americans with early and established 
rheumatoid arthritis (RA). Using a cross-sectional case-only design, CRP SNPs were genotyped in 
two independent sets of African Americans with RA: Consortium for the Longitudinal Evaluation 
of African Americans with RA (CLEAR 1) and CLEAR 2. Radiographic data and CRP 
measurements were available in 294 individuals from CLEAR 1 [median (IQR 25-75) disease 
duration of 1 (0.6-1.6) year] and in 407 persons from CLEAR 2 [median (IQR 25-75) disease 
duration of 8.9 (3.5 – 17.7) years]. In CLEAR 1, in adjusted models, the minor allele of rs2808630 
was associated with total radiographic score [incident rate ratio (IRR) 0.37 (95% CI 0.19-0.74), p 
value =0.0051]. In CLEAR 2, the minor allele of rs3093062 was associated with increased plasma 
CRP levels (p value =0.002). For each rs3093062 minor allele, the plasma CRP increased by 1.51 
(95% CI 1.15-1.95) mg/dL when all the other covariates remained constant. These findings have 
important implications for assessment of the risk of joint damage in African Americans with RA.
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Rheumatoid arthritis (RA), a common form of inflammatory arthritis affecting synovial 
joints, has a variable clinical expression ranging from mild disease to severe joint 
destruction 1. Although the biological processes underlying the pathophysiology of RA are 
not completely understood, systemic inflammation, as reflected by serum CRP levels, is 
thought to represent a key component. CRP is found in the synovial fluid of RA patients 2 
and can bind to lymphocytes, monocytes and other inflammatory cells 3–5. Serum CRP level 
is commonly used to assess disease activity in RA patients 6 and is part of the Disease 
Activity Score in 28 joints (DAS28-CRP) 7. Serum CRP levels are also included in the 
American College of Rheumatology (ACR) treatment response criteria 8. The importance of 
serum CRP in RA is also highlighted by the finding that levels of this acute phase reactant 
influences physicians’ decisions in changing treatment in RA 9.
Single nucleotide polymorphisms (SNPs) in CRP have been shown to be associated with 
serum CRP levels 10–13 and their biologic role has been evaluated in different disease states 
including RA, cardiovascular disease, Alzheimer’s disease, colorectal cancer, and chronic 
kidney disease 10, 14–17. For instance, among African-Americans without known 
cardiovascular disease, the minor allele of the CRP SNP rs3093058 is associated with higher 
serum CRP levels, while the minor allele of rs1205 is associated with lower CRP serum 
levels 12.
There is great variability in the minor allele frequency (MAF) of CRP SNPs among different 
ethnic groups 10, 18. CRP SNP rs3093058 is part of a haplotype associated with incident 
stroke in African-Americans 12, but this SNP is monomorphic (MAF=0) in European-
Americans and thus does not contribute to the risk of stroke in that ethnic group 12. 
Furthermore, the MAF of another haplotype-tagging SNP in CRP (rs3093066) is 0.23 in 
African-Americans, but this locus is monomorphic in persons of European ancestry 18. 
Given the relevance of CRP to RA pathogenesis and clinical decision making, such 
differences in genotype distributions could have important implications for pathogenesis in 
patients with RA.
CRP is indisputably a component of the inflammatory process in RA, and plasma CRP 
levels are associated with radiographic damage among RA patients 19. However, the 
relationship between radiographic damage in RA and genetic variants within CRP has not 
explicitly been investigated, particularly in understudied ethnic minority populations. In the 
current study, we measured plasma CRP levels and genotyped 11 polymorphic SNPs in CRP 
in a sample of well-characterized African Americans with RA with early disease (CLEAR 1) 
and with predominantly long-standing disease (CLEAR 2). Thus, these analyses provide 
insight into the role of CRP at different phases of the disease. Specifically, we tested 
whether CRP polymorphisms were associated with radiographic severity and with plasma 
CRP levels in early and longstanding disease to evaluate whether systemic inflammation and 
RA-induced joint damage have common genetic determinants.
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The baseline characteristics of the study samples are presented in Table 1. More detailed 
information about the clinical characteristics of the CLEAR participants has been previously 
published 20. Table 1 shows that compared with African Americans with RA from CLEAR 
1 subset, the participants enrolled in CLEAR 2 had more radiographic damage, were older, 
had longer disease duration, a lower median tender joint count, were more likely to be 
autoantibody positive (RF and ACPA). In addition, there were differences in use of 
DMARDs and biologic agents. Because enrollment in CLEAR 1 occurred between 2000 and 
2005, a relatively low percentage (~4%) of participants used biologic agents (etanercept, 
infliximab and anakinra). Enrollment in CLEAR 2 occurred between 2006 and 2011, so a 
higher percentage (~36%) of participants had been on biologic agents (etanercept, 
infliximab, anakinra, adalimumab, abatacept or rituximab). Disease activity score (DAS28) 
could not be calculated in the CLEAR 1 participants, since global health scores by visual 
analog scale were not available. However we were able to calculate DAS28-3(CRP) using 
total joint count, swollen joint count, and CRP level using the formula DAS28-3(CRP) = 
(0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP+1))* 1.10 + 1.15, which we 
have reported in detail previously21. The Pearson correlation between the CRP SNPs and 
DAS28-3(CRP) ranged from −0.09 and 0.09. Since global health scores by visual analog 
scale were available in CLEAR 2, we were able to calculate DAS28(CRP) with 4 variables. 
The Pearson correlation between CRP SNPs and DAS28(CRP) ranged from −0.12 and 
0.07. Thus, as expected, there was no demonstrable association between DAS28 scores 
(which vary widely during the patient’s course, depending on flare/remission status) and 
CRP genotype.
Associations of CRP polymorphisms with total radiographic scores
The median (IQR 25-75) mTSS at enrollment in CLEAR 1 was 0 (0–2), while in CLEAR 2, 
the median (IQR 25-75) mTSS was 6 (0–31), as previously reported 20. As noted above, 
mTSS of 0 was noted in 200 (68%) CLEAR 1 participants and 248 (61%) CLEAR 2 
participants. The results of the univariate and multivariate analyses for the associations of 
CRP genotypes with mTSS are shown in Tables 3 and 4. In the multivariate analysis of 
CLEAR 1, the minor allele of CRP variant rs2808630 was associated with lower total 
radiographic score after adjusting for RA disease duration, age, gender, autoantibody status 
(RF and ACPA), CRP level and use of traditional or biologic DMARD [IRR 0.37 (95% CI 
0.19-0.74), p value=0.0051] (Table 3). For each C allele of the rs2808630, the mTSS 
decreased by 73% (95% CI 26-81%) when all the other covariates remained constant. 
Because ancestry could potentially confound the association between rs2808630 and the 
total radiographic score, we tested the mean European admixture proportion across 
genotypes for rs2808630. The proportion of European admixture was available for 69% of 
the CLEAR 1 participants included in the analysis. The mean (SD) European admixture 
proportion was 0.18 (0.05), 0.19 (0.12), 0.16 (0.1) for rs2808630 CC, CT and TT 
respectively. There was no statistically significant difference in the proportion of European 
admixture across the genotypes (p=0.26), which demonstrates that the proportion of 
European admixture does not confound the association between rs2808630 and total 
radiographic score. In fact, after adjustment for the proportion of European admixture, 
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there was an association between the minor allele of CRP variant rs2808630 and lower 
total radiographic score [IRR 0.43 (95%CI 0.19-0.97), p value=0.0432] (Table 3). None of 
the CRP SNPs was associated with radiographic severity in CLEAR 2 after adjusting for 
relevant covariates (Table 4).
Associations of CRP polymorphisms with plasma CRP levels
The results of the univariate and multivariate analyses for the associations of CRP 
polymorphisms with baseline plasma CRP are shown in Tables 5 and 6. After adjusting for 
age, gender, BMI, number of swollen and tender joints, autoantibody status, and 
corticosteroid use, CRP genotype rs3093062 was associated with increased plasma CRP 
levels in CLEAR 2 [mean estimate (95% CI) 0.18 (0.06-0.29), p=0.0021] (Table 6) . Thus, 
for each rs3093062 A minor allele, the plasma CRP increased by 1.51 (95% CI 1.15-1.95) 
mg/dL when all the other covariates remained constant. The proportion of European 
admixture was available for 83% of the CLEAR2 participants included in the analysis. After 
adjusting for the proportion of European admixture, the CRP genotype rs3093062 was 
associated with increased plasma CRP levels in CLEAR 2 [mean estimate (95% CI) 0.19 
(0.07-0.32), p=0.0028] (Table 6).
DISCUSSION
This is the first study to evaluate the association of genetic variation in CRP locus with joint 
damage in RA and is focused on an important minority racial/ethnic group. We found that 
rs2808630 in the CRP 3’ flanking region was associated with radiographic damage in early 
RA (CLEAR 1) and identified statistically significant associations between a CRP promoter 
region SNP, rs3093062, and higher levels of plasma CRP in African Americans with 
established RA. Our results are concordant with a recent report from Plant et al. 22, which 
found that CRP rs3093062 was associated with increased plasma CRP in RA patients from 
the UK. However, in contrast to Rhodes et al. 13, we did not find an association between 
CRP SNPs rs1205 and plasma CRP levels in early RA, possibly due to differences in 
ethnicity (UK, New Zealand and Australians). Most importantly, we found that the CRP 
locus influences both radiographic damage and plasma CRP levels at different stages of the 
disease. A possible explanation for the finding of different CRP SNPs associated with 
phenotypes in early and established disease is that there are significant differences in the 
clinical and demographic characteristics between the two groups analyzed, early vs 
established. Alternatively, it is possible that the pathobiology of early RA is different than 
that of established RA (i.e. the activity of different transcription factors is affected by CRP 
SNPs in early versus established RA). In an attempt to test this theory, we analyzed the 
association of rs2808630 and total radiographic scores in 60 CLEAR 2 participants with 
disease duration of less than 2 years. We found that the CRP rs2908630 was not associated 
with less radiographic damage (IRR =0.61, p=NS), but the direction of the effect was 
similar to the results obtained in CLEAR1. This result suggests that future studies of CRP 
genetic variation and radiographic severity are warranted in early RA.
A major strength of this study is that it analyzes the largest group of African Americans with 
RA available to date. Several clinical (age, sex, disease duration, medication use, disease 
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activity), laboratory (autoantibody positivity, CRP level, ESR), genetic (HLA DRB1 shared 
epitope) and environmental (smoking) factors previously reported to contribute to structural 
joint damage in RA 23, 24. This paper is the first to provide evidence of a CRP genetic 
contribution to structural joint damage in African Americans with RA, independent of age, 
gender, disease duration, DMARD use, and autoantibody status (RF and ACPA status). The 
association of CRP SNP rs2808630 with lower radiographic damage has biological 
plausibility, because of previous literature supporting an association between this variant 
and lower CRP levels in a much larger sample of African Americans (~2,100) from the 
Third National Health and Nutrition Examination Survey (NHANES III) 10.
Previous studies have shown that the radiographic damage in RA is heritable, with the h2 
estimate ranging from 45 to 58% 25. Our study adds to the growing body of evidence in 
support of genetic associations with radiographic severity in multiple populations: IL1 
cluster 26, TNFa 27, 28, IL4R 29, 30, TRAF1-C5, TNFAIP3-OLIG3 31, 32, 6q23 region, IL10, 
IL6, CD40, 31, 33–35, MMP3 36, PTPN22, RANKL, IL17 37. There is mixed support in the 
literature for a correlation between HLA-DRB1 SE alleles and radiographic 
damage 28, 37–40 27. We did not specifically include any of these non-HLA loci in our 
models, but we did include HLA-DRB1 SE status and did not find an association of SE 
status and radiographic severity. This is consistent with findings of Khanna et al. in a study 
of Caucasians with early RA 27. In our study, the absence of association between SE alleles 
and radiographic severity may be due to a lower frequency of HLA-DRB1 SE alleles in 
African Americans compared to European ancestry RA 41.
The present study represents a candidate SNP approach aimed at defining the contribution of 
7 CRP polymorphisms to joint damage in RA. Future fine mapping of CRP may identify 
more genetic variants linked to radiographic severity and plasma CRP levels in African 
Americans with RA. Because our study included only African Americans, the association of 
CRP variants with radiographic severity is not generalizable to the entire population of 
patients with RA and further studies in other ethnicities are needed to address this issue.
In summary, among African Americans with early RA after taking in consideration clinical 
relevant factors, CRP rs2808630 is associated with lower radiographic damage, while CRP 
rs3093059 is associated with increased plasma CRP levels in African Americans with RA 
independent of other factors. These findings have important implications for assessment of 
disease activity and risk of erosive disease in African Americans with early RA.
MATERIALS AND METHODS
Study population
The CLEAR 1 Registry enrolled African Americans with RA between 2000 and 2005 and 
included only patients with less than 2 years disease duration. CLEAR 2 enrolled African 
Americans with RA between 2006 and 20#11 and included RA of any disease duration 20. 
Patients enrolled in CLEAR 1 were not enrolled in CLEAR 2, so there was no overlap in the 
patient populations. All participants met revised 1987 American Rheumatism Association 
(now the American College of Rheumatology) criteria 42, and were self-declared African-
Americans of 19 years of age and older. After signing informed consent, the participants 
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were recruited in Alabama (University of Alabama at Birmingham – Coordinating Center), 
Georgia (Emory University), North Carolina (University of North Carolina at Chapel Hill), 
Missouri (Washington University), and South Carolina (The Medical University of South 
Carolina). Peripheral blood was collected for measurement of rheumatoid factor (RF), anti-
cyclic citrullinated peptide antibodies (ACPA), plasma CRP and for isolation of genomic 
DNA. Questionnaires were administered to document current and previous drug treatments 
with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. We included 
in this analysis sets of page#11hand/wrists (postero-anterior views) and feet (antero-
posterior views) radiographs obtained at enrollment and scored using the modified 
Sharp/van der Heijde scoring system and assigned a modified total Sharp score 
(mTSS) 20, 43. Participants provided written informed consent and human subject protocols 
were approved by the Institutional Review Boards of the participating institutions.
The following socio-demographic variables were included as covariates in the analyses: age 
at enrollment, sex, disease duration, body mass index (BMI), and smoking status (ever vs. 
never). The clinical variables included were: tender and swollen joint counts (assessed in 28 
joints - shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal 
joints, and knees), usage of methotrexate and other DMARDs, biologic agents, and 
corticosteroids.
CRP levels (mg/L) were measured on plasma samples from the enrollment visits at the 
Clinical and Epidemiological Research Laboratory at Children’s Hospital in Boston using a 
high-sensitivity immunoturbidimetric assay on a Hitachi 917 autoanalyzer (Roche 
Diagnostics, Indianapolis, IN), with the use of reagents and calibrators from Denka Seiken 
(Tokyo, Japan). High levels of CRP were defined as > 3 mg/L 44. RF and ACPA were 
assayed as previously reported 45. We measured plasma rather than serum CRP levels 
because of the availability of plasma specimens for our study population and because the 
measurement of CRP in plasma and serum are comparable 46.
Genotyping methods
Eleven CRP SNPs (rs3093058, rs3093059, rs2794521, rs3093061, rs3093062, rs3091244, 
rs1417938, rs1800947, rs3093066, rs1205, rs2808630) were selected for genotyping based 
on several criteria at the time of study inception: disease associations reported in the 
literature; minor allele frequency > 5% in published databases; or potential biological 
function 10, 11, 18, 47, 48 (see Table 2). For 347 CLEAR 1 participants and 143 CLEAR 2 
participants, 9 of the CRP SNPs were genotyped using Applied Biosystems (ABI) TaqMan® 
Genotyping Assays, (Foster City, CA) on an ABI 7900HT Sequence Detection System with 
a call rate of greater than 99%. The tri-allelic SNP rs3091244 SNP and the bi-allelic SNP 
rs3093061 were genotyped by Pyrosequencing 49 using Biotage (Charlotte, NC) reagents 
and protocol; the call rate for both was 99%. For 440 CLEAR 2 participants, genotype data 
of rs3093059, rs2794521, rs3093062, rs3093066, rs1205, rs2808630 were available as part a 
of a previous genotyping effort through the Immunochip (iChip) custom array by Illumina 
(San Diego, CA); these markers had a call rate greater than 98.5%. One CRP polymorphism 
(rs1800947) had a MAF of 0.005 and thus was not included in the analysis. HLA DRB1 
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genotyping was performed using the Atria Genetics (South San Francisco, CA) AlleleSEQR 
DRB1 reagents and protocol as previously described 41.
Statistical methods
Means (SD) were calculated for normally distributed continuous variables and proportions 
were calculated for categorical variables. Student t tests and chi square tests were used to 
evaluate differences between continuous and categorical variables, respectively. Linkage 
disequilibrium (LD) between biallelic SNP pairs was analyzed using Haploview 50 
(Supplemental Figure 1). CRP polymorphisms rs3093061, rs3093058, and rs3093062 were 
in tight LD (pairwise r2 > 0.8), as were rs2808630 and rs2794521; only one CRP SNP from 
each of these two sets (rs3093062 and rs2808630) was included in the data analysis. As 
noted above, one CRP polymorphism (rs1800947) had a MAF of < 1% and was excluded 
from the data analysis. Genotype data for CRP SNPs rs3091244 and rs1417938 was 
available for analysis in only 140 (~34%) CLEAR 2 participants. There were no significant 
differences in the MAF of the CRP SNPs between CLEAR 1 and CLEAR 2 (data not 
shown). Deviation from HWE for each of the CRP polymorphisms was assessed using 
Haploview. All the CRP SNPs analyzed were in HWE.
We performed separate data analysis in the two study groups: CLEAR 1 and CLEAR 2 for 
several reasons, including different enrollment periods (2000 – 2005 for CLEAR 1; 2006 – 
2011 for CLEAR 2), different available medications, different disease duration, and 
differences in degree of radiographic damage. Complete data on genotypes, radiographic 
scores, and CRP measurements were available for 294 (83%) of the 355 CLEAR 1 
participants and 407 (57%) of the 712 CLEAR 2 participants. There were no statistically 
significant differences in clinical and biochemical characteristics between the persons for 
whom radiographs were available and the entire study population (data not shown).
The modified total radiographic score (mTSS) for these two groups of patients was over-
dispersed, with the majority having no damage (mTSS=0) in 200 (68%) of CLEAR 1, and 
248 (61%) of CLEAR 2 participants. Thus, negative binomial models were fitted to evaluate 
the association of CRP genotypes (explanatory variable) with the mTSS (dependent 
variable) in an additive genetic model framework. Given the positively skewed distribution 
of the plasma CRP levels, these values were log-transformed for the purposes of the 
analysis. Linear regression was used to investigate the relationship between CRP genotypes 
and log transformed plasma CRP levels, assuming an additive genetic model of inheritance. 
Demographic and clinical variables with p value < 0.25 in the univariate analyses were 
included in the multivariate analyses 51. In addition, since gender, CRP levels and traditional 
and biologic DMARD use have been shown to affect the progression of radiographic joint 
damage, these covariates were included in multivariable models with mTSS as the outcome 
variable. The final multivariable models were adjusted for the proportion of European 
admixture, which was available for 69% of the participants in CLEAR 1 and 83% 
individuals in CLEAR 2 as part a of a previous genotyping effort through the Immunochip 
(iChip) custom array by Illumina (San Diego, CA). Bonferroni correction was used to adjust 
for multiple comparisons for both the primary (mTSS) and secondary (log transformed CRP 
level) outcomes. After removing SNPs with low MAF and those in tight linkage 
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disequilibrium from the analysis (see Methods), 7 independent SNPs remained. Thus, for the 
association analysis, we considered statistical significance to be achieved at the alpha = 
0.05/7=0.0071.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of African American participants with RA from CLEAR registry.
Variable CLEAR 1 CLEAR 2
(N=294) (N=407)
Age, years, mean (SD) 50.7 (13.4) 56.4 (11.8)
Age at diagnosis, years, mean (SD) 49.6 (13.4) 44.9 (12.7)
BMI, kg/m2, mean (SD)1 31.3 (7.6) 31.9 (7.7)
Disease duration, years, median (IQR 25–75) 1 (0.6–1.6) 8.9 (3.5–17.7)
Swollen joint count, median (IQR 25–75) 4 (1–9) 5 (1–13)
Tender joint count, median (IQR 25–75) 7 (2–18) 6 (2–14)
Gender, female, N(%) 242 (82.3) 349 (85.8)
Smoking, ever, N(%)2 156 (53.2) 210 (51.6)
RF status, positive, N(%)3 204 (70.3) 328 (80.8)
ACPA status, positive, N (%)4 183 (63.1) 292 (71.9)
Shared epitope status, present, N (%)5 122 (41.5) 154 (37.9)
Corticosteroids, ever, N(%)6 154 (79.8) 379 (93.8)
Synthetic DMARD use, ever, N (%)7 247 (84) 388 (98.5)
Biologic DMARD use, ever, N (%)8* 12 (3.9) 145 (35.9)
mTSS, median (IQR 25–75) 0 (0–2) 6 (0–31)
Percent European admixture, mean (SD)9 17(10.6) 15.4 (9.3)
CRP, mg/dl, median (IQR 25–75)10 5.1 (1.8–9.4) 4.2 (1.5–8.9)
Abbreviations: ACPA, anti-cyclic citrullinated peptide antibodies; CLEAR, Consortium for the Longitudinal Evaluation of African-Americans 
with Early Rheumatoid Arthritis; CRP, C-reactive protein; DMARDs, disease modifying anti-rheumatic drugs; IQR, interquartile range; mTSS, 
modified total Sharp score; RA, rheumatoid arthritis; RF, rheumatoid factor; SD, standard deviation; SE, shared epitope;
1
Missing for 17 persons;
2
Missing for 1 person;
3
Missing for 5 persons;
4
Missing for 5 persons;
5
Missing for 1 persons;
6
Missing for 104 persons;
7
Missing for 2 persons;
8
Missing for 3 persons;
9
Missing for 159 persons;
10
Missing for 5 persons.
*
Biologic DMARDs: etanercept, infliximab, adalimumab and anakinra.
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